DTNB: A Potential Drug Target and Biomarker for the Treatment of Depression

Target Name: DTNB

NCBI ID: G1838

DTNB

DTNB: A Potential Drug Target and Biomarker for the Treatment of Depression

Depression is a common and debilitating mental disorder that affects millions of people worldwide. According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and it is estimated that it will be the second leading cause of death by the year 2030.

While traditional treatments for depression, such as antidepressants, have been effective in managing symptoms, there is still a need for more effective and targeted treatments. This is whereDTNB comes in.

DTNB stands for dopamine-targeting neurotransmitter-binding protein, and it refers to a protein that is expressed in the brain and is involved in the transmission of dopamine, a neurotransmitter that plays a crucial role in mood regulation.

Research has shown that dopamine is often imbalanced in people with depression, and that this imbalance can contribute to the persistent symptoms of depression. By targeting the dopamine system, DTNB may provide a new and more effective treatment for depression.

One of the key benefits of DTNB is its ability to selectively target dopamine-receptors, rather than all neurotransmitters. This allows for a more targeted and effective treatment, and can reduce the potential for unintended side effects.

In addition, DTNB has been shown to have anti-depressant effects in animal models of depression, and to be safe and well-tolerated in human trials. This suggests that it may be a promising new treatment option for depression.

DTNB is also a potential biomarker for depression. By measuring the levels of DTNB in the brain, researchers can track the effectiveness of different treatments and determine which ones are most effective. This may help to improve the accuracy and effectiveness of future treatments for depression.

Moreover, DTNB has the potential to be used in combination with other treatments for depression. By targeting the dopamine system and providing additional targets for depression, it may have a more comprehensive effect on mood regulation.

In conclusion, DTNB is a promising new drug target and biomarker for the treatment of depression. With its selective targeting of dopamine-receptors and its anti-depressant effects in animal models, it has the potential to be an effective and well-tolerated new treatment option for depression. Further research is needed to confirm its effectiveness and to develop it into a safe and effective treatment for depression.

Protein Name: Dystrobrevin Beta

Functions: Scaffolding protein that assembles DMD and SNTA1 molecules to the basal membrane of kidney cells and liver sinusoids (By similarity). May function as a repressor of the SYN1 promoter through the binding of repressor element-1 (RE-1), in turn regulates SYN1 expression and may be involved in cell proliferation regulation during the early phase of neural differentiation (PubMed:27223470). May be required for proper maturation and function of a subset of inhibitory synapses (By similarity)

The "DTNB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DTNB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets